Research & Development

Non Alcoholic Fatty Liver Disease

PYN22 for Non Alcoholic Fatty Liver Disease

Non Alcoholic Fatty Liver Disease ("NAFLD") is a common and increasing problem world wide. It encompasses a spectrum of liver disorders ranging from fatty liver to non-alcoholic steatohepatitis (‘NASH’), the latter being associated with liver inflammation and fibrosis. NAFLD may progress through NASH to cirrhosis and heptocellular carcinoma. Currently there is no effective drug therapy in use for NAFLD/NASH. Treatment focuses on reducing body weight by diet and exercise and for more severe cases associated with morbid obesity, bariatric surgery. PYN22 is a single plant extract that has been selected as a candidate for the treatment of NAFLD/NASH, based on preclinical work in both China and the UK that suggests PYN22 may have a direct effect on body weight, liver and blood fat levels. Phynova has plans in development for a clinical study with PYN22 that it expects to initiate during 2008.